47 results
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
to an authorization from the Human Research Ethics Committee (“HREC”).
The trial was a Phase 2 randomized triple-blind active-placebo-controlled trial … institutional review board (“IRB”) or ethics committee at each clinical trial site before each clinical trial may be initiated;
performance of adequate
S-1/A
IXHL
Incannex Healthcare Limited
17 Jul 24
IPO registration (amended)
8:47am
Human Research Ethics Committee (“HREC”) for the conduct of the BA/BE clinical trial. As of April 2024 participant recruitment and dosing is ongoing … of the FDA 505(b)2 approval pathway that IHL is targeting with IHL-675A.
Approval from the Human Research Ethics Committee to conduct the phase 1 study
S-1
IXHL
Incannex Healthcare Limited
3 Jul 24
IPO registration
6:29am
the FDA505(b)2 regulatory pathway.
Approval was received in July 2023 from Bellberry Human Research Ethics Committee (“HREC”) for the conduct of the BA … -675A.
Approval from the Human Research Ethics Committee to conduct the phase 1 study was received in July 2022. Participant recruitment commenced
8-K
IXHL
Incannex Healthcare Limited
22 Dec 23
Clarion Clinics Receives Ethics Board Endorsment for the First Dedicated Psychedelic-assisted Therapy Clinic In Australia
6:07am
Australian subsidiary, Clarion Clinics, received endorsement from the Australian Human Research Ethics Committee for the administration of psychedelic
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
22 Dec 23
Clarion Clinics Receives Ethics Board Endorsment for the First Dedicated Psychedelic-assisted Therapy Clinic In Australia
6:07am
Exhibit 99.1
Date: December 21, 2023
Public Announcement (NASDAQ: IXHL)
CLARION CLINICS RECEIVES ETHICS BOARD ENDORSMENT FOR THE FIRST DEDICATED … PSYCHEDELIC-ASSISTED THERAPY CLINIC IN AUSTRALIA
Highlights:
Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC
8-K
EX-14.1
m5w17qtxm zz4wll4p
29 Nov 23
Entry into a Material Definitive Agreement
4:36pm
8-K
u6n0g
29 Nov 23
Entry into a Material Definitive Agreement
4:36pm
6-K
EX-99.1
j9whigivbzyem8g3manx
26 Oct 23
Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
6:02am
6-K
EX-99.1
xnqk2kw4bp2g
1 Sep 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
y5o74jyb59xt3pshh9
27 Jul 23
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
8:47pm
6-K
EX-99.1
oywv0 qn3x
13 Jul 23
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
6:02am
6-K
ygzqo6u o3nkqo5wy
5 Jul 23
Report of Foreign Private Issuer
8:47pm
6-K
EX-99.1
droi4w 6jss50
5 Jul 23
Report of Foreign Private Issuer
8:47pm
6-K
EX-99.1
n6mdud20
15 Jun 23
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
9:06pm
6-K
EX-99.1
u3e2zcl322tm4ytc1
2 May 23
Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
12:00am
20-F
yta 0epjtt
28 Oct 22
Annual report (foreign)
6:31am
6-K
EX-99.1
t4pff3lh
19 Sep 22
Report of Foreign Private Issuer
9:38pm
6-K
EX-99.1
d36pp66
9 Aug 22
Report of Foreign Private Issuer
6:01am
6-K
EX-99.1
vmppsiyq5jvwq2
28 Jul 22
Incannex Healthcare Quarterly Activities Report and Appendix 4C
2:35pm